ACC 2022

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

C. Michael Gibson and Duk-Woo Park discuss the ADAPT-TAVR Trial presented at ACC 2022.

We Recommend